Takeda touts late-stage diabetes data; New drugs for cachexia; Burrill vet raising Canada biotech fund;

@FierceBiotech: Brain switch turns 'on' when danger hits, 'off' when threat passes. Item | Follow @FierceBiotech

@JohnCFierce: MDV3100 release this a.m. includes new survey on specialists, desire for new prostate cancer drugs. Release | Follow @JohnCFierce

@RyanMFierce: Help me find the world's smartest biotech techies for new Fierce special report: Report | Follow @RyanMFierce

@FierceMedDev: AngioDynamics' new chief playing offense and ready for risk. Via @Business_Review. Article | Follow @FierceMedDev

>Takeda is offering up late-stage data showing its diabetes drug TAK-875 reduced blood sugar just as well as a generic, but with fewer side effects. Only 2% of the patients taking the experimental drug developed hypoglycemia, compared with 19% in the generic arm. Story

> The Los Angeles Times covers new efforts by GTx and Helsinn to develop treatments for cachexia, the loss of muscle and weight among patients suffering from cancer. Report

> Burrill veteran Ann Hanham tells the Globe and Mail that she's out trying to raise a $200 million fund to invest in Canada's biotech companies. "It is heartbreaking that so much talent and so much brilliant research isn't being commercialized," she tells the newspaper. Story

> Affymax says it has earned a $5 million milestone from Takeda. Story

> With an eye to developing the market for the promising prostate cancer drug MDV3100, Medivation cites a new survey showing that virtually all the practitioners in the field see the need for new therapies. Release

Pharma News

@FiercePharma: Glenmark pulls 7 lots of contraceptive pills on a packaging error that could cause incorrect dosing/pregnancy risk. Article | Follow @FiercePharma

> J&J chief gets stepped-up bonus for 2011. News

> Cost and job cuts coming soon to Merck KGaA. Article

Medical Devices News

> Autonomic tackles migraines with neurostimulation tech. Article

> InSightec scores $13.75M from GE. Story

> Wright sees quarterly sales, net income drop. News

> Can U.S. ensure access to a 2nd diagnostic test? Item

IT News

> Roche getting entire workforce to use Google Apps. Story

> Startup aims to tap wisdom of the crowd for low-cost drug trials. Article

> J&J hires Selventa to build computerized models for personalized medicine. News

> Algorithm may expose drug targets for Alzheimer's. More

> OmniComm licenses clinical trials software to CRO Pharma Medica. Item

And Finally… Scientists at MIT and the Ragon Institute believe that a software program used to track stock prices could be a valuable tool in discovering a vaccine for HIV. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.